Physician profile
Maria E Johnson
NPI 1033300728
$4,365.49
in general payments reported to CMS, 2019-2025
28 companies · $577 in 2025
The $577 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $220 · 2021: $269 · 2022: $381 · 2023: $1,200 · 2024: $1,046 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807 · Education: $16.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,807.39 |
| Education | $16.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,372.94 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $549.47 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $371.19 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $304.03 | 2019-2025 | Stelara, Tremfya, Simponi |
| Ardelyx, INC. | $261.34 | 2022-2025 | Ibsrela |
| Celgene Corporation | $199.81 | 2022-2024 | Zeposia |
| Janssen Pharmaceuticals, INC | $170.16 | 2020-2021 | |
| Lilly USA, LLC | $137.17 | 2024-2025 | Omvoh |
| Pfizer INC. | $131.12 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $91.92 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $85.39 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $85.01 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $84.26 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $70.42 | 2023-2024 | Ocaliva |
| Qol Medical, LLC | $67.95 | 2023-2024 | Sucraid, Sucraid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $64.98 | 2019-2020 | |
| Exact Sciences Corporation | $59.79 | 2024-2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $47.76 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Madrigal Pharmaceuticals | $41.22 | 2025 | Rezdiffra |
| Allergan, INC. | $27.25 | 2019 | |
| Aimmune Therapeutics, INC. | $27.03 | 2025 | Zenpep |
| Amgen INC. | $25.30 | 2025 | Uplizna |
| Ucb, INC. | $22.45 | 2019 | |
| Conmed Corporation | $19.13 | 2019 | |
| Shire North American Group INC | $17.18 | 2019 | |
| Celltrion USA INC. | $16.37 | 2024 | Zymfentra |
| Genzyme Corporation | $14.85 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.